Other News

Orchestra BioMed™ Strengthens Operations, R&D and Pharmaceutical Development Expertise with Key Leadership Team Additions

NEW HOPE, Pa., Oct. 10, 2018 (GLOBE NEWSWIRE) — Orchestra BioMed, Inc. (“Orchestra BioMed” or the “Company”), a biomedical innovation company developing high impact, high value, evidence-based therapeutic solutions for medical procedures that address major medical conditions, announced today that it has appointed three key members to its management team. Joining the […]

iRhythm Technologies to Report Third Quarter Financial Results on October 30, 2018

SAN FRANCISCO, Oct. 09, 2018 (GLOBE NEWSWIRE) — iRhythm Technologies, Inc. (NASDAQ: IRTC), a leading digital healthcare solutions company focused on the advancement of cardiac care, today announced that it will release financial results for the third quarter 2018 after the close of trading on Tuesday, October 30, 2018.  The company’s […]

Cardialen Closes $17 Million Series B Financing for Heart Rhythm Therapy

MINNEAPOLIS–(BUSINESS WIRE)–Cardialen, Inc., a medical device company developing a low-energy implantable defibrillation therapy designed to more gently restore normal heart rhythm, announced today the closing of a $17 million Series B investment led by RiverVest Venture Partners, along with Qiming Venture Partners, HBM Healthcare Investments and Cultivation Capital. The financing will […]

Concept Medical Inc. Raises $60mn for Investigational Device Exemption (IDE) for the World’s First Sirolimus-Coated Balloon

SURAT, India, Oct. 9, 2018 /PRNewswire/ — Concept Medical Inc. Raises $60mn For Investigational Device Exemption (IDE) For The World’s First Sirolimus-Coated Balloon. Concept Medical Inc. (CMI) has approached the FDA for an Investigational Device Exemption (IDE) for their Sirolimus-Coated Balloon (DCB). To support this process, they have raised $60mn (for an undisclosed valuation) from cardiologist and […]

Neovasc Reducer™ Granted Breakthrough Device Designation from FDA

VANCOUVER, Oct. 10, 2018 /PRNewswire/ – Neovasc Inc. (“Neovasc” or the “Company”) (NASDAQ: NVCN) (TSX: NVCN), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies and in the development of minimally invasive devices for the treatment of refractory angina, today announced that the U.S. Food and Drug Administration (the “FDA”) […]

Cagent Vascular Appoints Medical Device Industry Veteran Brian Walsh as Chairman of the Board

WAYNE, Pa.–(BUSINESS WIRE)–Cagent Vascular®, a developer of next generation angioplasty balloons using proprietary serration technology, announces Brian Walsh to serve as Chairman of the Board. Brian Walsh has held several executive level positions in cardiovascular and ophthalmology specialties within the medical device industry. Mr. Walsh currently serves as the President […]

Hemostemix Announces Three Additional Sites Enrolled in Phase II Clinical Trial

CALGARY, Alberta, Oct. 09, 2018 (GLOBE NEWSWIRE) — Hemostemix Inc. (“Hemostemix” or the “Company”) (TSX VENTURE: HEM) is pleased to announce that it has received all approvals from three new medical centers to be clinical trial sites for the Company’s Phase II clinical trial for critical limb ischemia (“CLI”).  In […]

Orchestra BioMed™ Adds Three Industry Leaders to Strategic Advisory Board

NEW HOPE, Pa., Oct. 09, 2018 (GLOBE NEWSWIRE) — Orchestra BioMed, Inc. (“Orchestra BioMed” or the “Company”), a biomedical innovation company developing transformational therapeutic devices targeting major medical conditions, announced today the appointment of three new members to its Strategic Advisory Board (“SAB”). Joining the Company’s SAB is Gary J. Pruden, former […]

Bellerophon Provides Update on INOpulse® Phase 2b Clinical Program for Treatment of Pulmonary Hypertension Associated with Interstitial Lung Disease

WARREN, N.J., Oct. 09, 2018 (GLOBE NEWSWIRE) — Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company, today provided an update on the Company’s ongoing Phase 2b randomized, double-blind, placebo-controlled clinical study (iNO-PF) evaluating INOpulse® in patients with Pulmonary Hypertension associated with Interstitial Lung Disease (PH-ILD), as […]

Hancock Jaffe Enters into Sponsored Research Agreement for CoreoGraft with World-Renowned Texas Heart Institute

IRVINE, Calif., Oct. 09, 2018 (GLOBE NEWSWIRE) — Hancock Jaffe Laboratories, Inc. (Nasdaq: HJLI, HJLIW), a company specializing in medical devices that restore cardiac and vascular health, announced today that it has entered into a Sponsored Research Agreement with Texas Heart Institute for the development of HJLI’s CoreoGraft®, an off […]